Can Sacituzumab govitecan cure triple-negative breast cancer?

Sacituzumab govitecan initially received accelerated approval in April 2020 for the treatment of patients with metastatic triple-negative breast cancer who have received at least two prior treatments for metastatic disease. The FDA granted full regulatory approval to gosatuzumab based on a Phase III trial. This antibody-drug conjugate consists of a monoclonal antibody targeting Trop-2 and contains SN-38, the active metabolite of irinotecan, as a cytotoxic moiety. In phase III clinical trials, gosatuzumab showed a median progression-free survival of 5.7 months compared with 1.7 months with chemotherapy.

Previously chemotherapy was the only treatment option for metastatic triple-negative breast cancer (mTNBC), which had a decreased survival rate. Trophoblast surface antigen-2 (Trop-2) may be a target for antibody-drug conjugates (ADCs). Treatment with gosatuzumab is now an additional option for patients with metastatic triple-negative breast cancer who have received at least two prior treatments for metastatic disease. For the treatment of triple-negative breast cancer, gosatuzumab has shown certain efficacy, but each patient's situation is different, and the efficacy may vary from person to person.

Gosatuzumab The original drug has been launched in China, but it has not yet been included in the medical insurance. The price of a 100mg bottle may be around 10,000 yuan, which is relatively expensive. Gosatuzumab Original drug marketed overseas has three versions: European version, American version, and Singapore version. SpecificationsThe price of each 100 mg bottle may be around RMB 10,000-35,000 (the price may fluctuate due to exchange rates). The ingredients of gosatuzumab sold domestically and abroad are basically the same. There is currently no generic version of gosatuzumab available on the market. For specific prices and drug information, please consult your medical consultant.